The second fiscal quarter for pSivida, which ended Dec. 31, 2017, brought a net loss of $5.8 million compared with a net loss of $67,000 in the previous year’s second quarter.
Revenues totaled $933,000 in the quarter compared with $6 million the previous year, according to a press release. The second fiscal quarter of 2016 had included $5.6 million in collaborative research and development revenue from the termination of a collaboration agreement with Pfizer.
Research and development expenses increased from $3.165 million in 2016’s second fiscal quarter to $4.269 million, while
Uncategorized